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Abstract
Background
Hepatitis B virus (HBV) reactivation in patients with resolved HBV infection (HBsAg nega-
tive, antiHBc positive) is uncommon, but potentially fatal. The role of HBV prophylaxis in this
setting is uncertain. The aim of this study was to compare the efficacy of tenofovir disoproxil
fumarate (TDF) prophylaxis versus close monitoring in antiHBc-positive, HBsAg-negative
patients under treatment with rituximab (RTX)-based regimens for hematologic malignancy.
Methods
PREBLIN is a phase IV, randomized, prospective, open-label, multicenter, parallel-group
trial conducted in 17 hospitals throughout Spain. Anti-HBc-positive, HBsAg-negative
patients with undetectable HBV DNA were randomized to receive TDF 300 mg once daily
(Group I) or observation (Group II). The primary endpoint was the percentage of patients
showing HBV reactivation during 18 months following initiation of RTX treatment. Patients
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with detectable HBV DNA (Group III) received the same dose of TDF and were analyzed
together with Group I to investigate TDF safety.
Results
Sixty-one patients were enrolled in the study, 33 in the TDF treatment group and 28 in the
observation group. By ITT analysis, HBV reactivation was 0% (0/33) in the study group and
10.7% (3/28) in the observation group (p = 0.091). None of the patients in either group
showed significant differences in liver function parameters between baseline and the last fol-
low-up sample. TDF was generally well tolerated and there were no severe treatment-
related adverse events.
Conclusion
In patients with hematological malignancy and resolved hepatitis B infection receiving RTX-
based regimens, HBV reactivation did not occur in patients given TDF prophylaxis.
Introduction
Patients with chronic hepatitis B virus (HBV) infection are at risk of viral reactivation while
receiving chemotherapy for malignant disease, including hematologic malignancies[1]. In
addition to those with serologic evidence of active infection (hepatitis B surface antigen
[HBsAg]-positive status), patients with resolved HBV infection (HBsAg-negative and antibody
to hepatitis B core antigen [anti-HBc]-positive with or without hepatitis B surface antibody
[antiHBs]) are also susceptible to HBV reactivation [2,3]. The role of HBV prophylaxis in
patients with resolved HBV is uncertain. In general, 2 approaches have been applied: close
observation with frequent monitoring and initiation of antiviral treatment when HBV-DNA is
detected, or prophylactic antiviral therapy. Nonetheless, no standard therapy has been estab-
lished and many questions remain in relation to this patient population [2–4].
HBV reactivation has been diagnosed using several criteria. The classic definition estab-
lishes reactivation on a serum HBV DNA increase of>1 log10 IU/mL or a10-fold increase
from baseline, or de novo HBV DNA detection [2–4]. When reactivation is associated with an
increase in alanine aminotransferase (ALT) levels, patients may have a poorer prognosis [4,5].
To prevent reactivation, it is crucial to identify HBV-infected patients at risk of this event prior
to starting immunosuppressive therapy [6,7]. The associated risk factors include viral status,
host factors, the underlying disease, and the therapy regimens received [8]. A combination of
several of these factors has been used to classify patients as having a high, intermediate, or low
risk [9–11].
HBV reactivation in HBsAg-positive patients under chemotherapy has been widely reported
in several diseases, including hematologic malignancies and solid tumors, such as breast cancer
[3,12]. Although reactivation is less common in anti-HBc-positive individuals, it has been
described in patients with lymphoma [13] receiving rituximab (RTX)-based regimens [14,15].
RTX is a chimeric monoclonal antibody against the protein, CD20, which is primarily found on
the surface of B cells [3]. This drug has potent immunosuppressant effects and is currently used
to treat many diseases, including hematologic malignancies, some rheumatological diseases and
other autoimmune disorders [16,17]. RTX-induced HBV reactivation rates range from 30% to
60% in HBsAg-positive patients [10,18] and in up to 25% of patients with antiHBc-positive,
HBsAg-negative resolved infections [19–23].
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The clinical manifestations of HBV reactivation vary from asymptomatic self-limiting hepa-
titis to severe, potentially fatal liver failure [13,24,25]. Furthermore, reactivation can impede
patients from adequately meeting their scheduled chemotherapy cycles, resulting in delays or
even interruptions of this treatment, with the subsequent risk of worsening the underlying
malignant disease [26]. The reported HBV reactivation rate during or after cessation of cancer
chemotherapy varies widely and greatly depends on the underlying disease and the treatment
regimens. Hence, identification of HBV-infected patients enables implementation of proper
antiviral therapy or prophylaxis, as well as careful monitoring.
In HBsAg-positive patients with malignant disease, the related guidelines recommend
[14,27,28] oral antiviral therapy at the time immunosuppression is started. In patients with an
indication for HBV therapy (defined by elevated ALT levels and HBV DNA>2000 IU/mL),
currently either tenofovir disoproxil fumarate (TDF) or entecavir (ETV) should be started and
maintained until the therapeutic endpoints for chronic HBV infection have been reached. In
HBsAg-positive patients without an indication for HBV therapy, prophylactic therapy is rec-
ommended regardless of the presence of HBV DNA.
Most of the experience in HBV prophylaxis has been with lamivudine. However, TDF and
ETV are less likely to lead to drug resistance and more likely to result in viral suppression than
lamivudine [29]. Huang et al, conducted a randomized controlled trial including 121 HBsAg-
positive patients receiving chemotherapy with RTX, cyclophosphamide, doxorubicin, vincris-
tine, and prednisone (R-CHOP) and either lamivudine (100 mg/day) or ETV (0.5 mg/day)
prophylaxis. [30]. HBV reactivation was defined as HBsAg detection and/or a confirmed
increase in HBV DNA levels1 log10 IU/mL from baseline. The results showed significantly
lower reactivation rates (6.6% vs. 30%, p = 0.001) and HBV-related hepatitis (0% vs. 13%,
p = 0.003) in patients receiving ETV than in those given lamivudine [30]. To date, there are no
trials comparing TDF with lamivudine or ETV, but it is anticipated that TDF should perform
as well as ETV [29]. In patients with resolved HBV infection (HBsAg-negative, antiHBc-posi-
tive) receiving RTX-based regimens, the role of HBV prophylaxis is still unclear.
The present randomized study (PREBLIN) aimed to compare the efficacy of TDF prophy-
laxis vs no therapy in the prevention of HBV reactivation in anti-HBc-positive, HBsAg-nega-
tive patients treated with RTX for hematologic malignancy.
Patients and methods
PREBLIN (EudraCT:2011-000905-30) is a prospective, randomized, open-label, multicenter, par-
allel-group, phase IV trial conducted in the liver and hematologic units of 17 hospitals in Spain.
Participant flow diagram is shown in Fig 1. The study design flowchart is summarized in Fig 2.
The protocol for the study was approved by the Spanish Agency for Medicines and Health
Products (SAMHP) and the Ethics Committee of Vall d’Hebron Hospital in 2011. All patients
were fully informed about the details of the study and patients provided written informed con-
sent before screening. The ethical principles outlined in the Declaration of Helsinki and Good
Clinical Practice were followed.
Patients were recruited from September 2011 to February 2014. After a baseline visit, fol-
low-up visits were scheduled every 2 months, over a period of 18 months. All information was
collected on an electronic case report form (eCRF).
Eligibility criteria
Patients with hematological malignancy receiving RTX either as monotherapy or in combina-
tion with chemotherapy were eligible. The inclusion criteria were age18 years, prior sero-
logic evidence of HBV exposure (anti-HBc positive), HBsAg-negative status, undetectable
Tenofovir as prophylaxis for hepatitis B virus reactivation
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Fig 1. Consort flow diagram.
https://doi.org/10.1371/journal.pone.0184550.g001
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HBV viral load (<lower limit of quantification), signed informed consent, and willingness to
comply with the indications of the investigator and study protocol. Patients were excluded if
they had any condition considered a contraindication for any of the study treatments, HIV co-
infection, presence of hepatocellular carcinoma, moderate/severe renal failure—based on
either an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 using the Modifi-
cation of Diet in Renal Disease (mDRD) formula or creatinine clearance <60 mL/min accord-
ing to the Cockcroft-Gault formula [31]—a neurological or lung condition believed to affect
participation in the study, participation in a clinical trial or receiving treatment with any unap-
proved drug for the previous 30 days, and pregnant or nursing women.
Study groups
Before starting RTX treatment, patients with undetectable HBV DNA were randomized into 2
groups: Group I, patients receiving TDF 300 mg once daily and Group II, patients under
observation, with analytical monitoring to detect HBV reactivation. To assure a 1:1 proportion
between randomized patients in each participating hospital, a block randomization design was
applied. An additional group (Group III) contained patients with detectable HBV DNA, who
were all treated with TDF for ethical reasons. In accordance with the study protocol, patients
in Group III were analyzed together with Group I to investigate TDF safety.
Follow-up visits
Patients were followed for a period of 18 months. Follow-up visits and blood tests were per-
formed every 2 months. At each visit the following were assessed: vital signs, liver function
parameters (aspartate [AST] and alanine [ALT] aminotransferases, gamma-glutamyl transfer-
ase [GGT], alkaline phosphatase [ALP], bilirubin, albumin, and platelets) renal function
parameters (serum creatinine, eGFR, creatinine clearance, and serum phosphorus), HBV
serology and HBV DNA level (COBAS AmpliPrep/COBAS TaqMan HBV Monitor Test;
Roche Diagnostics), RTX treatment cycles, and adverse effects.
Fig 2. Study design.
https://doi.org/10.1371/journal.pone.0184550.g002
Tenofovir as prophylaxis for hepatitis B virus reactivation
PLOS ONE | https://doi.org/10.1371/journal.pone.0184550 September 12, 2017 5 / 14
Primary endpoint
The primary endpoint was the percentage of RTX-treated patients in the 2 groups with unde-
tectable HBV-DNA levels (Group I and Group II) showing HBV reactivation within the 18
months of follow-up. Reactivation was defined by HBsAg and/or HBV DNA detection, or a
confirmed1 log10 IU/mL increase in HBV DNA levels from baseline.
Secondary endpoints
Secondary endpoints were the changes in liver and renal function test results between baseline
and the last follow-up visit in patients receiving TDF (Groups I and III) and those under obser-
vation (Group II). Additional secondary endpoints were the incidence of ALT flares (defined
by>5-fold ALT increase), liver failure, survival, and the safety analysis findings (including
TDF-related adverse events).
Statistical analysis
A standard statistical analysis was performed using R (3.10.0 version) software.
According to the available scientific evidence [19–23, 26], the sample size calculation was
based on the assumption that the incidence of HBV reactivation would be 0% in patients
receiving TDF 300 mg/daily and 20% in the observation group. To obtain significant differ-
ences between the 2 groups based on the Fisher exact test, at least 78 patients were required in
total, at a significance level of 0.05 and power of 0.80.
Data are expressed as the number (percentage), mean and standard deviation (SD), mean
(range), or median (range), as appropriate.
Intent-to-treat (ITT) efficacy analyses included all patients who received the study medica-
tion and had at least one valid visit. Per protocol analyses, which excluded patients who did
not complete the study or who had major protocol violations, were also conducted to confirm
the ITT results.
The Mann-Whitney U test or Wilcoxon signed rank test were used to compare quantitative
variables, as appropriate. To assess differences between parameters at baseline vs follow-up
month 18, the Friedman dependent sample test was applied. Categorical variables were com-
pared using the chi-square test or Fisher exact test, as appropriate.
Results
A flowchart showing inclusion of patients in the study is shown in Fig 3. Sixty-three patients
were screened and 61 met the inclusion/exclusion criteria and were enrolled between Septem-
ber 2011 and February 2014. Thirty-three were included in the TDF arm (Group I + Group
III) and 28 were assigned to the observation arm (Group II). The rate of all-cause study discon-
tinuations was 9.1% in the TDF group and 14.3% in the observation group.
No statistically significant differences between the TDF group and observation group were
found for patient demographics; mean (SD) age was 69.9 (13.3) years in the TDF group and 71
(9.02) years in the observation group, p = 0.968. The main baseline demographic and clinical
characteristics of the patients are summarized in Table 1.
HBV reactivation
By ITT analysis, HBV reactivation was 0% (0/33) in the TDF-treated group and 10.7% (3/28)
in the observation group (p = 0.091). These results were confirmed in the per protocol analysis
(TDF, n = 30; observation, n = 24): HBV reactivation was 0% (0/30) in patients receiving TDF
and 12.5% (3/24) in those under observation, p = 0.082.
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Of the 3 patients with HBV reactivation in the observation group, 2 were satisfactorily res-
cued with TDF therapy according to the criteria of the investigator, and the last remained
untreated Table 2).
Liver and renal functional tests
Between-group comparisons were carried out with the Wilcoxon signed ranked test and
within-group comparisons with the Friedman test. The between-group analyses showed no
significant differences in the baseline and month 18 liver function parameter values. Within-
group analyses showed significant differences in certain renal function parameters relative to
baseline in both arms at 18 months. Within-group comparisons between the baseline and final
analytical values are shown in Table 3.
Adverse events
TDF was generally well-tolerated in the patient population studied. There were no significant
differences between the TDF and observation groups in terms of the incidence of adverse
events (27.2% [9/33] vs. 25.0% [7/28], respectively; difference (95% CI) between the 2 groups
2.2% (-22.1% to 25.4%), p = 0.8468).
Eight severe adverse events were reported in the TDF group, including respiratory tract
infection (n = 4); sepsis (n = 2); asthenia (n = 1); mucositis/cellulitis (n = 1); and hemato-
logic toxicity (n = 1). Seven severe adverse events were reported in the observation group,
including respiratory tract infections (n = 4) and febrile neutropenia (n = 3). These events
were disease or immunosuppression-related complications and were unrelated to TDF ther-
apy. During follow-up, 9 patients died, 4 in the TDF group and 5 in the observation group.
The reported deaths were related to the hematological disease and not to the HBV prophy-
laxis administered.
Fig 3. Study population.
https://doi.org/10.1371/journal.pone.0184550.g003
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Table 1. Demographic, serologic and hematologic characteristics of patients included in the intent to treat (ITT) analysis.
Characteristic Group I(TDF, n = 29) Group II(Observation, n = 28) P value
Age, years
Mean (SD) 69.9 (13.3) 71.04 (9.02) 0.968#
Median 72.62 72.53
Sex, n (%)
Male 16 (55.2) 18 (64.3) 0.592&
Female 13 (44.8) 10 (35.79
Race, n (%)
White 29 (100) 27 (96.4) 0.986¥
Other* 0 (0) 1 (3.
Weight, Kg
Mean (range) 72.06 (47.0–94.0) 74.1 (43.2–122.0) 0.876#
Median 73.15 70.25
BMI, Kg/m2
Mean (range) 26.6 (17.2–34.0) 27.6 (19.1–39.0) 0.441#
Median 26.4 27.2
AntiHBc positive, n (%) 29 (100) 28 (100) 1.000&
AntiHBs positive, n (%)** 18 (62.1) 21 (75.0) 0.508&
Time since HBV diagnosis, years
Mean (range) 2.6 (0–23) 3.3 (0–40) 0.371#
Median 0.06 0.14
Time with HBsAg negative, years
Mean (range) 1.8 (0–23) 2.2 (0–40) 0.879#
Median 0.0 0.0
Time with HBeAg positive, years
Mean (range) 1.5 (0–20) 3.2 (0–40) 0.590#
Median 0.0 0.0
Malignancy, n (%)***
Non-Hodgkin lymphoma 19 (73.0) 20 (71.4) 0.312¥
Chronic lymphatic leukemia 5 (19.2) 6 (21.4)
Nodular sclerosis Hodgkin lymphoma 1 (3.9) 0 (0)
Nodal marginal lymphoma 1 (3.9) 1 (3.6)
Nodal marginal zone lymphoma 0 (0) 0 (0)
MALT lymphoma 0 (0) 1 (3.6)
Rituximab cycles
Mean (SD) 5.38 (4.2) 6.36 (3.07) 0.293#
Median 5 5.5
* Hispanic
** Information missing in 4 patients, 2 in each group
*** Information missing in 3 patients
# p-values in the comparison of Group I vs Group II, Mann Whitney U test
& p-values in the comparison of Group I vs Group II, Fisher Exact test
¥ p-values in the comparison of Group I vs Group II, chi-square test
Abbreviations: TDF, tenofovir disoproxil fumarate; SD, standard deviation; BMI, body mass index; anti HBc, anti-hepatitis B core antibody; antiHBs, anti-
hepatitis B surface antibody; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; MALT, mucosa-associated lymphoid tissue
https://doi.org/10.1371/journal.pone.0184550.t001
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Discussion
In this study, there was a non-significant trend suggesting a prophylactic effect of TDF in the
prevention of HBV reactivation in patients with hematologic malignancy receiving RTX-based
treatment regimens. None of the patients given this therapy experienced HBV reactivation
during the study period.
Several studies have suggested that RTX incorporation into standard chemotherapy regi-
mens increases the risk of HBV reactivation in patients with resolved HBV infection [21]. In a
Table 2. Characteristics of patients with HBV reactivation.
Patient 1 Patient 2 Patient 3
Age, years 85 83 61
Sex Female Male Male
Baseline Anti-HBsAg negative Anti-HBsAg negative Anti-HBsAg negative
Seroconversion (HBs-
Ag+)
No No Yes
RTX cycles 9 11 6
Reactivation Increase of HBV-DNA1 log10 IU/mL at
visit month 4
Increase of HBV-DNA 1 log10 IU/mL at
visit month 4
Increase of HBV-DNA1 log10 IU/mL at visit
month 4and 12.
ALT levels ALT always <40 IU/L with a maximum
value of 15 IU/L
ALT always <40 IU/L with a maximum
value of 15 IU/L
Month 12: ALT = 163 U/L & AST = 100U/L
Month 14: ALT = 155 U/L & AST = 67 U/L.
Rescued with TDF TDF N/A
HBV-DNA after-rescue Undetectable at month 6 visit Undetectable at month 6 visit N/A
Abbreviations: HBsAg, hepatitis B surface antigen; RTX, rituximab; HBV, hepatitis B virus; ALT, alanine aminotransferases; AST, aspartate
aminotransferases; TDF, tenofovir disoproxil fumarate; N/A, not available
https://doi.org/10.1371/journal.pone.0184550.t002
Table 3. Liver and renal function test results at baseline and at month 18 of follow-up.
Group I + Group III (TDF), n = 33 Group II (Observation), n = 28
Liver function, mean
(range)
N Baseline Month 18 P* N Baseline Month 18 P*
ALT, IU/L 26 22.7 (9–95) 27.9 (9–110) 0.
339
19 20.6 (7–60) 22.2 (8–89) 0.84
AST, IU/L 26 27.0 (9–68) 28.3 (14–94) 0.52 17 19.9 (9–67) 19.7 (11–44) 0.365
GGT, IU/L 22 62.5 (6–611) 31.3 (8–77) 0.156 15 65.3 (11–496) 30.2(10–87) 0.345
Bilirubin, mg/dL 24 0.7 (0.32–2.3) 0.6 (0.2–1.3) 0.92 18 0.7 (0.2–1.4) 0.7 (0,7–1.8) 0.85
Albumin, g/dL 19 5.9 (2.2–4,9) 4.3 (3.6–4.8) 0.235 17 4.0 (2.9–4.8) 4.3 (3.7–4.8) 0.39
Alkaline phosphatase, IU/L 22 110 (32–360) 25.5 (72–362) 0.119 16 90.3 (49–234) 90.9 (40–191) 0.32
Platelets/mm3 26 194,670.3 (5,100–
568,000)
184,419 (49,500–
337,000)
0.657 19 203,096 (21,000–
367,000)
189,578 (64,000–
274,000)
0.084
Renal function, mean
(range)
Baseline Month 18 P* Baseline Month 18 P*
Serum creatinine, mg/dL 26 0.8 (0.4–1.2) 0.9 (0.6–1.3) 0.054 18 0.9 (0.5–1.2) 1.0 (0,.5–1.4) 0.03
GFR, mL/min/1.73 m2 26 93.7 (62.2–205.1) 81.6 (57.4–111.8) 0.071 18 86.6 (61.3–136.5) 77.6 (40.2–149.6) 0.034
Creatinine clearance 26 86.5 (51.2–286.4) 77.3 (38.4–145.6) 0.022 18 81.0 (37.8–168.8) 75.5(23.0–145.3) 0.016
Phosphate, mg/dL 18 3.2 (1.2–4.4) 3.1 (2.2–4.1) 0.17 11 3.2 (2.0–4.3) 3.3(2.1–4.1) 0.541
* P-values obtained using the Friedman test for dependent samples, comparing baseline vs month 18.
ALT, alanine aminotransferases; AST, aspartate aminotransferases; GGT, gamma-glutamyltransferase; GFR, glomerular filtration rate; TDF, tenofovir
disoproxil fumarate
https://doi.org/10.1371/journal.pone.0184550.t003
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meta-analysis including anti-HBc-positive patients, HBV reactivation rates were more than
5-fold higher in patients receiving RTX [32].
Antiviral prophylaxis with oral drugs such as lamivudine (LAM), ETV, and telbivudine, ini-
tiated concurrently or prior to immunosuppressive therapy in patients with chronic or
resolved HBV infection reduces the incidence of HBV reactivation, the severity of associated
hepatitis, and mortality [29,30,33]. The drugs currently available for the management of
chronic hepatitis B include LAM, adefovir, ETV, telbivudine, and TDF. By far, the largest body
of literature on the prevention of HBV reactivation is focused on the role of LAM, the first of
these drugs to be available. A meta-analysis including 774 HBsAg-positive patients with solid
tumors who received antiviral prophylaxis during chemotherapy reported that the risk of HBV
reactivation was lowered by approximately 90% (odds ratio [OR] 0.12, 95% CI 0.06–0.22) [33].
In addition, antiviral prophylaxis was associated with fewer cases of HBV-related hepatitis
(OR 0.18, 95% CI 0.10–0.32) and chemotherapy interruptions (OR 0.10, 95% CI 0.04–0.27).
Nonetheless, there were no significant reductions in acute liver failure or death [33].
LAM is associated with a high rate of drug resistance (up to the 20% within the first 12
months of use) [34, 35]. Nucleos(t)ides showing higher efficacy and substantially lower antivi-
ral resistance rates than LAM, such as ETV or TDF, may be better options to mitigate HBV
reactivation [29]. The currently available evidence indicates that in addition to positive treat-
ment effects, TDF has potent inhibitory effects on HBV DNA replication and the capacity to
ameliorate liver fibrosis and cirrhosis [36–39].
Few studies have evaluated the efficacy of prophylactic antiviral therapy with TDF in
HBsAg-negative, anti-HBc-positive patients receiving chemotherapy. In a real-life study con-
ducted in 2014, Koskinas et al [40] assessed the impact of TDF on HBV reactivation in patients
undergoing immunosuppressive therapy. The study included 38 immunosuppressed patients
who received antiviral treatment with TDF (as prophylaxis in 25 patients and as treatment for
HBV reactivation in 13 patients). In all 25 patients receiving prophylactic TDF treatment,
there were no HBV flares during immunosuppression and serum HBV-DNA levels became or
remained undetectable during the follow-up period (mean, 17 months) [40]. In agreement
with the findings from this study, none of our 33 immunosuppressed patients receiving TDF
prophylactic therapy exhibited HBV reactivation.
Experimental and clinical studies have detected minor effects on the kidney with TDF use,
such as enlargement of tubular epithelium nuclei and accumulation of hyaline droplets [41].
At 18 months of follow-up in the present study, TDF-treated patients showed a significant
reduction in creatinine clearance relative to baseline, whereas the observation group showed
significant reductions in both creatine clearance and the glomerular filtration rate. These find-
ings suggest that the renal function impairment detected was not related to TDF, but more
likely an effect of the chemotherapy given or the disease, itself.
This study has the evident limitation that the difference in the HBV reactivation rate
between patients receiving TDF and those under close monitoring was not statistically signifi-
cant. Only a trend to significance was found suggesting that TDF is effective for this purpose.
Nonetheless, we believe that the scarcity of data on prophylaxis with this drug in HBsAg-nega-
tive, anti-HBc-positive patients receiving chemotherapy will make these preliminary findings
of value for clinicians.
It is likely that the main reason for the lack of significance was that the calculated sample
size was not reached. Seventeen centers participated and the recruitment period was extended
to 3 years, but we were unable to reach the number required. Certain factors contributed to
this situation. First, to achieve a proper sample, the inclusion criteria were quite restrictive,
and the study was done within real-world clinical practice. A standard screening procedure
has not been defined and adopted in daily practice to identify candidates for prophylaxis.
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Hence many patients do not receive adequate prophylaxis at initiation of cancer therapy and
before HBV-DNA levels rise, and this would make them ineligible for inclusion. Another
unforeseen factor was the low reactivation rate in the observation group. The expected rate
according to the information in the literature [19–23, 26] was 20% and this value was incorpo-
rated in the sample calculation. However, reactivation in the observation group was only 10%,
similar to the reactivation rates reported for patients receiving prophylactic LAM [35] or ente-
cavir [42]. Hence, detection of statistically significant differences in the comparison was fur-
ther compromised.
In summary, although significant differences were not found, the results of this study pro-
vide a clinically relevant indication that TDF is effective as prophylactic therapy for preventing
HBV reactivation in patients with hematologic malignancies and resolved HBV infection
receiving RTX. In addition, TDF was well tolerated with no discontinuations due to adverse
events or toxicity. Although further studies are needed to obtain definitive data, these findings
provide a useful indication of the value of TDF in this clinical setting.
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